Latest Sorafenib Stories
SAN DIEGO, Dec.
OTTAWA, Oct. 30, 2014 /CNW Telbec/ - Health Canada today released the October 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).
WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.
50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months SAN ANTONIO, Sept. 8, 2014 /PRNewswire/ -- GenSpera, Inc.
Eleven-month Increase in Median OS Reported with VT-122 plus Sorafenib, Compared to Sorafenib Alone.
Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market SAN ANTONIO, Sept.
CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience SAN ANTONIO, Aug.
POINT ROBERTS, Wash. and NEW YORK, Aug.
Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc.
- In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.